INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
TE
Corporate insider

Tamayo Louis Edward

Chief Financial OfficerCIK 0002083206

EDGAR filingsOpen in network
Disclosed transactions6
Buys / sells0 / 2
Max Insider Score36
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
54.8K sh
Sep 24, 2026Sep 28, 2026
traded Sep 24, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Lexeo Therapeutics, Inc.Chief Financial Officer · Feb 6, 2026
27
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL
$20K
4,117 sh
Aug 18, 2026
Aug 19, 2026
traded Aug 18, 2026
+1d
SEC FORM 4

Evidence

13
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
12.0K sh
Jun 29, 2026Jul 1, 2026
traded Jun 29, 2026
+2dSEC FORM 4

Evidence

36
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Open-market sale
SELL$21K
4,641 sh
Jul 1, 2026Jul 1, 2026
traded Jul 1, 2026
+0dSEC FORM 4

Evidence

9
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
226.7K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

21
TE
Tamayo Louis EdwardChief Financial Officer
LXEOLexeo Therapeutics, Inc.
Grant or award
A—
44.7K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence